Synplogen, established in 2017 and based in Kobe, Japan, is a synthetic biology start-up specializing in custom DNA synthesis and gene therapy biofoundry services. Utilizing proprietary technologies, the company can synthesize complex DNA sequences up to 100 kilobases, including those with high/low GC content and repeat sequences. As a biofoundry specializing in gene therapy, they also offer comprehensive support for gene therapy product development, encompassing sequence design, process development, analytical development, and quality control. The company has formed strategic alliances with companies like Ginkgo Bioworks and FUJIFILM Toyama Chemical to advance DNA manufacturing and mRNA therapeutics.